ACCESS AND EXCESS; Point of Care Diagnostics and Prepackaged Drugs for Integrated Fever Management for Malaria, Pneumonia and Diarrhoea in Private Sec
The main child killer diseases, malaria and pneumonia both present with fever and rapid breathing and overlaps with diarrhea. Without diagnostic tests health workers treat presumptively. In Uganda we have shown a majority of children dying from pneumonia had first been treated with malaria drugs. With poor access to quality public care, two thirds of febrile children in rural Uganda are treated from private drug shops, while drug resistance is mounting from excess use on the wrong indication. Point-of-care diagnostics for malaria and pneumonia and prepackaged quality drugs are now being introduced as Integrated Community Case Management (iCCM) through Community Health Workers to increase access. Meanwhile the private sector continues to see a majority of patients with poor quality and excess drug use. This project will assess effects of introducing diagnostics and promoting pediatric-dosage pre-packed drugs for acute febrile illnesses (malaria pneumonia diarrhoea) in private pharmacies in rural Uganda. Using a two-arm design comparing iCCM, to presumptive antimalarial treatment we evaluate the effect on appropriate and prompt treatment, quality of care, adherence and drug use. Household surveys, exit interviews, treatment register review and an adherence survey will be done, as well as qualitative interviews with parents and shopkeepers. Results will add to the meager evidence on private sector and inform ongoing Global Fund private sector interventions
- Project ID
SE-0-SE-29-2012-2872-285-12182
- Activity status
- 2 - Implementation
- Aid type
- D02 - Other technical assistance
- % to Uganda
- 100.00
Organisations
- Funding
- Sweden
- Extending
- The Swedish Research Council
- Implementing
- Uppsala universitet
Disbursements by fiscal year, quarter
Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
2015 |
Q2 |
77,111.98 |
77,111.98 |
2014 |
Q2 |
94,753.57 |
94,753.57 |
2013 |
Q2 |
99,797.33 |
99,797.33 |
Commitments by fiscal year, quarter
Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
2012 |
Q3 |
299,392.00 |
299,392.00 |
MTEF projections by fiscal year
Fiscal year |
Value (USD) |
Uganda Value (USD) |
CRS code |
% |
Medical research
(12182)
|
100.0
|